top of page

European Commission approves Gevalka ensartinib for ALK-positive advanced lung cancer

Writer: nuaxia
nuaxia
2 days ago
2 min read

The oral ALK inhibitor has secured final EU authorisation for previously untreated and crizotinib-treated ALK-positive advanced non-small cell lung cancer, following evidence of progression-free survival benefit.


On 16 November 2026, the European Commission granted marketing authorisation to Gevalka (ensartinib), with SFL Pharmaceuticals Deutschland GmbH as marketing authorisation holder, for adults with ALK-positive advanced non-small cell lung cancer.


The approval covers patients who have not previously received an ALK inhibitor and those previously treated with crizotinib, supported by evidence including improved progression-free survival compared with crizotinib in the first-line setting.

Field

Content

Alert Type

Approval

Product

Gevalka

Active Ingredient or Technology

Ensartinib; oral anaplastic lymphoma kinase inhibitor

Company or Marketing Authorisation Holder

SFL Pharmaceuticals Deutschland GmbH; Betta Pharmaceuticals associated with product development

Regulatory Authority

European Commission

Approval Type

Initial centralised European Union marketing authorisation

Approved Indication

Gevalka monotherapy for ALK-positive advanced non-small cell lung cancer in adults previously untreated with an ALK inhibitor or previously treated with crizotinib

Patient Population

Adults with ALK-positive advanced non-small cell lung cancer who are ALK-inhibitor-naive or previously treated with crizotinib

Therapy Area(s)

Oncology; lung cancer; ALK-positive non-small cell lung cancer

What Was Approved

The European Commission authorised ensartinib as an oral targeted monotherapy for two defined populations of adults with ALK-positive advanced non-small cell lung cancer.

Supporting Evidence

An open-label randomised active-controlled study demonstrated improved progression-free survival with ensartinib versus crizotinib in the first-line setting. Clinical data also showed relevant tumour response rates after prior crizotinib treatment.

Clinical Significance

The authorisation adds an oral ALK-targeted treatment option for biomarker-selected patients with advanced non-small cell lung cancer, including those previously treated with crizotinib.

Regulatory Context

The European Medicines Agency's CHMP issued a positive opinion on 17 September 2026. The European Commission granted final authorisation on 16 November 2026, recorded in the EU Union Register under EU/1/26/2078.

Key Takeaway

Gevalka has received final EU marketing authorisation for ALK-positive advanced non-small cell lung cancer in both ALK-inhibitor-naive and post-crizotinib adult populations.

What to Watch

Commercial availability, national pricing and reimbursement decisions, clinical adoption and further evidence on effectiveness and safety in routine practice.

Primary Source

https://ec.europa.eu/health/documents/community-register/html/reg_last.htm

Approval Date

16 November 2026


Discover how nuaxia can support your next medical education initiative:

Comments

Rated 0 out of 5 stars.
No ratings yet

Add a rating
bottom of page